ESMO 2025: Eli Lilly’s Verzenio extends survival in high-risk early breast cancer
These Phase III results could enhance Verzenio’s uptake alongside ET in the adjuvant breast cancer setting, if approved.
20 October 2025
20 October 2025
These Phase III results could enhance Verzenio’s uptake alongside ET in the adjuvant breast cancer setting, if approved.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.